Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia
Open Access
- 1 April 2021
- journal article
- research article
- Published by Taylor & Francis in Neuropsychiatric Disease and Treatment
- Vol. ume 17, 1195-1206
Abstract
Background and Objective: Essential thrombocythemia (ET) is a rare cause of cerebral venous sinus thrombosis (CVST). Analysis of the risk factors and treatment therapies of CVST in ET has yielded controversial findings. Subjects and Methods: We retrospectively investigated the clinical characteristics of CVST events in ET and compared baseline characteristics, causative factors, hematological effects, and treatments between ET patients with and without CVST. Results: Overall, 91 of 115 patients who met the ET diagnosis were included in this study. Among them, 23 (25.27%) patients met the diagnostic criteria of ET with CVST for inclusion, 14 (60.87%) of whom were females, with a median age of 34 (range 25– 50). CVST diagnosis was made concomitantly to ET in 19 patients (82.61%). The most common symptom and sites of thrombosis of CVST was an acute or subacute headache and sigmoid sinuses, respectively. Compared with ET patients without CVST, ET patients with CVST were significantly younger (37.65± 14.45 vs 60.93± 13.46, P< 0.001) and had lower prevalence of hypertension (4.34 vs 32.35%, P=0.003) and coronary artery disease (0 vs 14.71%, P = 0.045). Patients with CVST presented with significant lower platelet count (510.39± 176.71 vs 750.82± 249.10, P< 0.001) and higher score of IPSET-thrombosis (P=0.017). Multivariate logistic regression analysis indicated that age (P=0.002, OR 1.096, 95% CI 1.035– 1.161), at least one CVRF (P = 0.024, OR 0.037, 95% CI 0.002– 0.649), platelet count (P=0.045, OR 0.994, 95% CI 0.989– 1.001), and lower percentage of antiplatelet therapy (P=0.035, OR 0.307, 95% CI 0.001-1.280) significantly contributed to the risk of CVST in ET. Conclusion: Most patients (95.65%) had a favorable outcome without recurrence after standard anticoagulant and cytoreductive treatment at last follow-up. These findings indicate that CVST may be the initial presentation of ET, with its detection crucial for early diagnosis and appropriate management. Anticoagulant and cytoreductive therapies should be recommended for preventing ET-related CVST with JAK2 V617F mutation.Keywords
This publication has 30 references indexed in Scilit:
- Pathogenesis and Management of Thrombotic Disease in Myeloproliferative NeoplasmsSeminars in Thrombosis and Hemostasis, 2019
- Classification and Personalized Prognosis in Myeloproliferative NeoplasmsNew England Journal of Medicine, 2018
- Cerebral Venous Sinus Thrombosis Incidence Is Higher Than Previously ThoughtStroke, 2016
- The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemiaBlood, 2016
- Diagnosis and Management of Cerebral Venous ThrombosisStroke, 2011
- Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemiaInternal and Emergency Medicine, 2009
- Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithmsLeukemia, 2007
- Thrombosis in Myeloproliferative Disorders: Prevalence, Prognostic Factors, and the Role of Leukocytes and JAK2V617FSeminars in Thrombosis and Hemostasis, 2007
- Cerebral venous thrombosis: an updateThe Lancet Neurology, 2007
- Clinical Features of Polycythemia Vera and Essential Thrombocythemia in Japan: Retrospective Analysis of a Nationwide Survey by the Japanese Elderly Leukemia and Lymphoma Study GroupInternational Journal of Hematology, 2006